Data gathered: October 4
Alternative Data for Apellis Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 12 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 22,000 | Sign up | Sign up | Sign up |
| Employee Rating | 66 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | 43 | Sign up | Sign up | Sign up |
| App Downloads | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 12 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 3,694 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,676 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| X Mentions | 25 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 832 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 38 | Sign up | Sign up | Sign up |
| Linkedin Employees | 786 | Sign up | Sign up | Sign up |
About Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.
| Price | $23.80 |
| Target Price | Sign up |
| Volume | 3,490,000 |
| Market Cap | $3.01B |
| Year Range | $16.36 - $30.39 |
| Dividend Yield | 0% |
| Analyst Rating | 61% buy |
| Industry | Biotechnology |
In the news
 |
HC Wainwright Issues Pessimistic Outlook for APLS EarningsOctober 2 - ETF Daily News |
 |
Apellis Pharmaceuticals: Maintaining "Buy" Rating With Continued EMPAVELI Expansions Beyond PNH And C3G-DisordersSeptember 30 - SeekingAlpha |
 |
Wall Street Has a Mixed Opinion on Apellis Pharmaceuticals (APLS)September 30 - Yahoo Entertainment |
|
Wealth Enhancement Advisory Services LLC Purchases 30,507 Shares of Apellis Pharmaceuticals, Inc. $APLSSeptember 29 - ETF Daily News |
|
Apellis Pharmaceuticals (NASDAQ:APLS) Rating Lowered to Sell at The Goldman Sachs GroupSeptember 27 - ETF Daily News |
|
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap Down on Analyst DowngradeSeptember 26 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '25 | 178M | 14M | 164M | -42M | -30M | -0.330 |
| Q1 '25 | 167M | 34M | 132M | -92M | -80M | -0.740 |
| Q4 '24 | 213M | 41M | 172M | -36M | -24M | -0.290 |
| Q3 '24 | 197M | 34M | 163M | -57M | -44M | -0.462 |
| Q2 '24 | 200M | 24M | 176M | -38M | -28M | -0.280 |
Insider Transactions View All
| Dunlop A. Sinclair filed to sell 33,979 shares at $22.6. October 2 '25 |
| Dunlop A. Sinclair filed to sell 68,908 shares at $23. September 19 '25 |
| Watson David O. filed to sell 118,730 shares at $24.3. September 18 '25 |
| Chopas James George filed to sell 53,468 shares at $24.2. September 17 '25 |
| Watson David O. filed to sell 50,136 shares at $26.2. September 12 '25 |
Similar companies
Read more about Apellis Pharmaceuticals (APLS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, app downloads, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, x mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Apellis Pharmaceuticals?
The Market Cap of Apellis Pharmaceuticals is $3.01B.
What is the current stock price of Apellis Pharmaceuticals?
Currently, the price of one share of Apellis Pharmaceuticals stock is $23.80.
How can I analyze the APLS stock price chart for investment decisions?
The APLS stock price chart above provides a comprehensive visual representation of Apellis Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Apellis Pharmaceuticals shares. Our platform offers an up-to-date APLS stock price chart, along with technical data analysis and alternative data insights.
Does APLS offer dividends to its shareholders?
As of our latest update, Apellis Pharmaceuticals (APLS) does not offer dividends to its shareholders. Investors interested in Apellis Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Apellis Pharmaceuticals?
Some of the similar stocks of Apellis Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.